Caldolor, an intravenous form of ibuprofen that is used as a pain reliever and fever reducer, was recently approved by Australia's Therapeutic Goods Administration (TGA). Caldolor is manufactured by the Nashville, Tennessee-based pharmaceutical company, Cumberland Pharmaceuticals.
Caldolor will distributed in Australia by Seqirus; its Australian launch was the culmination of much effort by representatives of Cumberland and Seqirus.
"We are delighted to work with our partner Seqirus to bring Caldolor into Australia, offering a new level of patient care as ibuprofen advances to IV," A.J. Kazimi, Cumberland's CEO, said. "We have worked diligently with Seqirus to prepare for the introduction of Caldolor, which has been widely available in the U.S. with over one million doses sold since its launch in this country."
Caldolor is used primarily in hospital settings and can be used after surgery in place of opioids and other narcotics.
"We recognize that improving access to additional pharmacological options for post-operative pain is very important to Australian health care professionals and patients," Dr. Lorna Meldrum, Seqirus' vice president of Asia Pacific Commercial Operations, said.
